Agilent Technologies acquires Raman spectroscopy innovator, Cobalt Light Systems
Cobalt's portfolio of solutions accelerates entry into high-growth Raman spectroscopy market and expands Agilent’s value proposition for pharmaceutical and biopharma customers.
Agilent Technologies has acquired Cobalt Light Systems, a provider of highly differentiated Raman spectroscopic instruments for the pharmaceutical industry, applied markets and public safety.
Cobalt's innovative suite of benchtop and handheld/portable Raman spectroscopic instruments are based on proprietary technologies that enable through-barrier identification of chemicals and materials. Traditional solutions based on conventional spectroscopy have limited capacities for detection of materials through sealed, non-transparent containers and are constrained to near-surface identification of materials such as pharma tablet coatings and containers. By enabling measurement through opaque barriers and surfaces, Cobalt's solutions can analyse whole tablets or inside sealed containers reducing the need for quarantines and time-consuming sample processing and testing in pharmaceutical QC, hazardous chemical ID and security. The result is significant time, cost, and resource savings for customers, as well as increased safety for certain market segments such as first responders or air passengers.
Cobalt's customers include more than 20 of the largest 25 global pharmaceutical companies, and more than 75 airports across Europe and Asia-Pacific, including eight of the 10 largest European airports, with over 500 devices deployed at airport checkpoints. Recently, Cobalt has entered the hazardous substances markets with its handheld platform.
"Raman spectroscopy is one of the fastest-growing segments in spectroscopy," said Phil Binns, vice president and general manager of Agilent's Spectroscopy and Vacuum Solutions Division. "This acquisition gives our customers access to state-of-the-art Raman spectroscopy technology. It also provides Agilent immediate entry into this fast-growing segment with a highly competitive, differentiated offering."
"This is exactly the type of acquisition that Agilent's strategy calls for – one that expands our market share and provides immediate benefits to our customers," said Patrick Kaltenbach, president of Agilent's Life Sciences and Applied Markets Group. "We're focused on delivering best-in-class solutions to our customers, and Cobalt's Raman spectroscopy product and team meet and exceed that criterion."
"Cobalt and Agilent have similar cultures focused on customer-centric innovation," Cobalt CEO Paul Loeffen said. "The combination of Cobalt's patented technologies with Agilent's product-development expertise, manufacturing capabilities, channels and customer base will allow us to scale our operations to take advantage of this rapidly growing market."
Agilent is acquiring Cobalt for £40 million in cash.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.